tiprankstipranks
Xencor sees 2024 year end cash $690M-$710M
PremiumThe FlyXencor sees 2024 year end cash $690M-$710M
2M ago
Xencor doses first subject in first-in-human study of XmAb942
Premium
The Fly
Xencor doses first subject in first-in-human study of XmAb942
3M ago
Is XNCR a Buy, Before Earnings?
Premium
Pre-Earnings
Is XNCR a Buy, Before Earnings?
3M ago
Xencor announces offering of common stock and warrants, no amount given
PremiumThe FlyXencor announces offering of common stock and warrants, no amount given
4M ago
Xencor jumps after announcing four new XmAb programs
Premium
The Fly
Xencor jumps after announcing four new XmAb programs
4M ago
Xencor Reports Progress in Oncology and Autoimmune Therapies
Premium
Company Announcements
Xencor Reports Progress in Oncology and Autoimmune Therapies
4M ago
Xencor to regain exclusive rights to plamotamab
PremiumThe FlyXencor to regain exclusive rights to plamotamab
7M ago
Xencor price target raised to $36 from $34 at Wedbush
Premium
The Fly
Xencor price target raised to $36 from $34 at Wedbush
8M ago
Xencor reports Q1 EPS ($1.11), consensus (79c)
Premium
The Fly
Xencor reports Q1 EPS ($1.11), consensus (79c)
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100